NSC745885 an effectiveanti-tumoragent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator ofEZH2via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers^[1][2].

NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC₅₀of NSC745885 is 0.85 μM after 72 hours’ treatment^[1].
NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner^[1].
NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells^[1].

NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin^[1].

266.27

Solid

C₁₄H₆N₂O₂S

4219-52-7

Room temperature in continental US; may vary elsewhere.

DMSO :< 1 mg/mL(insoluble or slightly soluble)

*NSC745885 is usually formulated as a suspension.